Prange Group and its affiliate Adragos Pharma signed definitive agreements with Fresenius Kabi to acquire a sterile pharmaceutical production site in Halden, Norway. As part of the transaction, Fresenius Kabi will strike  a long-term supply agreement for products manufactured at the Halden site. The acquisition marks a milestone for both the Prange Group and Adragos Pharma expanding their global presence and adding significant capacity for sterile liquid manufacturing. 

According to the company, the Halden site, located at strategic crossroads in Norway, is one of the largest and most advanced  sterile production facilities in Northern Europe. The state-of-the-art capabilities include the production  of IV bags, ampoules, blow-fill-seal technology, and other pharmaceutical dosage forms. The site was the cornerstone of Fresenius Kabi’s manufacturing capabilities in the Nordics, and also caters  to other prominent pharma customers as a contract manufacturer.

Otto Prange, chairman of the Prange Group, said, “Our collaboration  with Fresenius Kabi is a strategic step that resonates with Prange Group’s commitment to quality and  reliability in supplying our customers and in caring for patients globally. Through our partnership with  Adragos Pharma, we are set to enhance the potential of the Halden site, which is a testament to the  dedication of Halden’s workforce. Recognizing the value of our employees, we are dedicated to fostering  their expertise, ensuring that the legacy and integrity of the site continue to thrive.”

Andreas Raabe, Adragos Pharma’s CEO, said, “The inclusion of the Halden site into Adragos  Pharma’s network is a fantastic addition to our network. Halden has a broad range of technologies and  offers considerable expansion space that allows us to tailor our services to the specific needs of our  customers. We will be positioning the site as one of Europe’s premier sterile production facilities.”